Strides Arcolab's arm starts construction of new facility in Malaysia

04 Dec 2014 Evaluate

Stelis Biopharma, a wholly owned subsidiary of Strides Arcolab, has started the construction of its customized, multi-product, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia. The construction and fit-out of the facility is expected to be completed in 24 months and commercial operations are targeted to begin mid-2017 at Bio-XCell Park.

The 140,000 square foot facility will incorporate ‘next-gen’ single-use bio-processing technology with both mammalian and microbial manufacturing suites. When complete, it will be one of the few Regulated Market approvable facilities in the Region with end-to-end capability including sterile fill-finish across all formats. The facility will also house an R&D unit to conduct scale-up and process development studies.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

878.65 -7.00 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×